These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 7137983)

  • 1. Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.
    de Clercq E; Zhang ZX; Sim IS
    Antimicrob Agents Chemother; 1982 Sep; 22(3):421-5. PubMed ID: 7137983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice.
    Park NH; Pavan-Langston D; de Clercq E
    Antiviral Res; 1983 Mar; 3(1):7-15. PubMed ID: 6870230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E-5-(2-bromovinyl)-2'-deoxyuridine vs. interferon in the systemic treatment of infection with herpes simplex virus of athymic nude mice.
    De Clercq E; Zhen-Xi Z; Descamps J; Huygen K
    J Infect Dis; 1981 Jun; 143(6):846-52. PubMed ID: 6166694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2'-deoxyuridine cream.
    Freeman DJ; Sacks SL; De Clercq E; Spruance SL
    Antiviral Res; 1985 Jun; 5(3):169-77. PubMed ID: 2992371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic efficacy of E-5-(2-bromovinyl)-2'deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice.
    Park NH; Pavan-Langston D; Boisjoly HM; De Clercq E
    J Infect Dis; 1982 Jun; 145(6):909-13. PubMed ID: 6979592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
    de Clercq E
    Antimicrob Agents Chemother; 1984 Aug; 26(2):155-9. PubMed ID: 6486759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine against different herpes simplex virus strains in cell culture and against experimental herpes encephalitis in mice.
    Reefschläger J; Wutzler P; Thiel KD; Bärwolff D; Langen P; Sprössig M; Rosenthal HA
    Antiviral Res; 1982 Oct; 2(5):255-65. PubMed ID: 6295273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis.
    Maudgal PC; De Clercq E; Descamps J; Missotten L; De Somer P; Busson R; Vanderhaeghe H; Verhelst G; Walker RT; Jones AS
    Antimicrob Agents Chemother; 1980 Jan; 17(1):8-12. PubMed ID: 7352751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs.
    Helbig B; Sauerbrei A; Klöcking R; Wutzler P; Wicht N; Wiedemann U; Herrmann G
    J Med Virol; 1987 Nov; 23(3):303-9. PubMed ID: 2828526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of the bioavailability of the anti-herpes virus agent BVDU by use of 5'-O-alkoxycarbonyl derivatives with increased metabolic stability.
    Boyd MR; Cole M; Harnden MR; Luk K; Rush MA; Sutton D; Hodge RA
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():207-13. PubMed ID: 3793660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir.
    Reefschläger J; Wutzler P; Thiel KD; Herrmann G
    Antiviral Res; 1986 Mar; 6(2):83-93. PubMed ID: 3010858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
    Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
    Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A quantitative study of the effects of several nucleoside analogues on established herpes encephalitis in mice.
    Field HJ; Anderson JR; Efstathiou S
    J Gen Virol; 1984 Apr; 65 ( Pt 4)():707-19. PubMed ID: 6323620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral and topical treatment of experimental HSV-1 genital herpes with (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Sim IS
    J Antimicrob Chemother; 1984 Aug; 14 Suppl A():111-8. PubMed ID: 6541647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bromovinyldeoxyuridine in the treatment of herpes simplex virus and varicella-zoster virus eye infections.
    Maudgal PC; De Clercq E; Missotten L
    Antiviral Res; 1984 Oct; 4(5):281-91. PubMed ID: 6335020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
    De Clercq E; Desgranges C; Herdewijn P; Sim IS; Jones AS; McLean MJ; Walker RT
    J Med Chem; 1986 Feb; 29(2):213-7. PubMed ID: 3005566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bromovinyldeoxyuridine therapy for herpes simplex and varicella-zoster virus infections in severely immunosuppressed patients: a preliminary clinical trial.
    Tricot G; De Clercq E; Boogaerts MA; Verwilghen RL
    J Med Virol; 1986 Jan; 18(1):11-20. PubMed ID: 3511181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
    Griengl H; Bodenteich M; Hayden W; Wanek E; Streicher W; Stütz P; Bachmayer H; Ghazzouli I; Rosenwirth B
    J Med Chem; 1985 Nov; 28(11):1679-84. PubMed ID: 4067994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients.
    Wildiers J; De Clercq E
    Eur J Cancer Clin Oncol; 1984 Apr; 20(4):471-6. PubMed ID: 6539202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
    De Clercq E
    Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.